Stilla raises 31M euros in financing

By The Science Advisory Board staff writers

November 23, 2021 -- Stilla Technologies has secured 31 million euros (about $35 million) in financing in the form of convertible bonds. The new funds will be used to further develop Stilla's global commercial presence and its next-generation digital polymerase chain reaction platform, the six-color Naica system, which it recently released.

In addition to new funding from existing investors Illumina Ventures, Kurma Partners, TusPark Capital Management, LBO France, BNP Paribas Developpement, and Eurazeo, Stilla attracted investment from life science firm Casdin Capital and the European Investment Bank.

Stilla launches Naica 6-color digital PCR system
Stilla Technologies has launched Naica, a digital polymerase chain reaction (PCR) system that features six fluorescent channels. Naica was introduced...
Stilla launches 6-color digital PCR system
Stilla Technologies has launched its six-color Crystal Digital PCR access program, which provides the industry with early access to its digital polymerase...

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter